282. Congenital dyserythropoietic anemia Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 4 / Drugs : 7 - (DrugBank : 3) / Drug target genes : 4 - Drug target pathways : 10
Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
Analysis OF genetic modifiers
Hospital Universitari Vall d'Hebron Research Institute
2020 - NCT07206095 Spain
Disease phenotyping
Hospital Universitari Vall d'Hebron Research Institute
2020 - NCT07206095 Spain
Luspatercept
FOndazione per la Ricerca sulle ANemie ed EMoglobinopatie in ItaliA - For Anemia
2023 Phase 2 EUCTR2020-005736-30-IT Italy
Omeprazole
Soroka University Medical Center
2013 Phase 4 NCT01795794 -
Reblozyl
FOndazione per la Ricerca sulle ANemie ed EMoglobinopatie in ItaliA - For Anemia
2023 Phase 2 EUCTR2020-005736-30-IT Italy
Zoledronic acid
Institute of Hematology & Blood Diseases Hospital, China
2026 Phase 1/Phase 2 NCT07471516 China
Hospital Universitari Vall d'Hebron Research Institute
2020 - NCT07206095 Spain
Disease phenotyping
Hospital Universitari Vall d'Hebron Research Institute
2020 - NCT07206095 Spain
Luspatercept
FOndazione per la Ricerca sulle ANemie ed EMoglobinopatie in ItaliA - For Anemia
2023 Phase 2 EUCTR2020-005736-30-IT Italy
Omeprazole
Soroka University Medical Center
2013 Phase 4 NCT01795794 -
Reblozyl
FOndazione per la Ricerca sulle ANemie ed EMoglobinopatie in ItaliA - For Anemia
2023 Phase 2 EUCTR2020-005736-30-IT Italy
Zoledronic acid
Institute of Hematology & Blood Diseases Hospital, China
2026 Phase 1/Phase 2 NCT07471516 China
